Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy

Kevin J. Klos, James H. Bower, Keith A. Josephs, Joseph Y. Matsumoto, J. Eric Ahlskog

Research output: Contribution to journalArticlepeer-review

230 Scopus citations

Abstract

Pathological hypersexuality developed in 13 patients with PD and two patients ultimately diagnosed clinically with MSA. Hypersexuality began within 8 months after starting dopamine agonist therapy in 14 of 15 cases, including four on agonist monotherapy. It resolved in the four cases where the agonist was stopped, despite continued levodopa therapy. This was not an isolated behavioral problem in most, with additional compulsive or addictive behaviors coinciding in nine patients (60%). A systematic literature review of pathological hypersexuality in PD revealed similar medication histories; combining these cases with our series, 26 of 29 patients (90%) were on adjuvant dopamine agonists.

Original languageEnglish (US)
Pages (from-to)381-386
Number of pages6
JournalParkinsonism and Related Disorders
Volume11
Issue number6
DOIs
StatePublished - Sep 1 2005

Keywords

  • Hypersexuality
  • Multiple system atrophy
  • Parkinson's disease
  • Parkinsonism

Fingerprint Dive into the research topics of 'Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy'. Together they form a unique fingerprint.

Cite this